Valentine’s Day has come and gone, and the weeks that follow are busy days for infectious disease doctors like me. Roses, chocolates, and hot dates give ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...